Production of Human Monoclonal Antibodies Using Epstein—Barr Virus

  • Dorothy H. Crawford


The Epstein—Barr virus (EBV) is a human lymphotrophic herpes virus that is the causative agent of infectious mononucleosis (Henle et al., 1968), and is also etiologically associated with two human tumors: African Burkitt lymphoma (Epstein and Achong, 1979) and nasopharyngeal carcinoma (Epstein, 1978). When used in vitro, the virus infects and transforms human B lymphocytes (Pattengale et al., 1973), which will thereafter grow continuously in culture as lymphoblastoid cell lines (Pope et al., 1968). EBV infection also causes polyclonal activation of B lymphocytes, with the synthesis and secretion of immunoglobulin (Rosen et al., 1977). The combination of these two properties of EBV makes it a useful tool for the immortalization of human antibody-secreting cells.


Human Monoclonal Antibody Tetanus Toxoid Infectious Mononucleosis Clone Cell Line Human MABS 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aman, P., Ehlin-Henriksson, B., and Klein, G., 1984, Epstein—Barr virus susceptibility of normal human B lymphocyte populations, J. Exp. Med. 159: 208–220.PubMedCrossRefGoogle Scholar
  2. Callard, R. E., 1979, Specific in vitro antibody response to influenza virus by human blood lymphocytes, Nature 282: 734–736.PubMedCrossRefGoogle Scholar
  3. Clarke, C. A., Donohue, W. T. A., McConnell, R. B., Woodrow, J. C., Finn, R., Krevans, J. R., Kulke, W., Lehare, D., and Sheppard, P. M., 1963, Further experimental studies on the prevention of Rh haemolytic disease, Br. Med. J. 1: 979.PubMedCrossRefGoogle Scholar
  4. Crawford, D. H., 1981, Lymphomas after cyclosporin A treatment, in: Transplantation and Clinical Immunology XIII U. T. Touraine, J. Traeger, H. Betuel, J. Brochier, J. M. Dubernard, J. P. Revillard, and R. Triau, eds.), Excerpta Medica, Amsterdam pp. 48–52.Google Scholar
  5. Crawford, D. H., Callard, R. E., Muggeridge, M. I., Mitchell, D. M., Zanders, E. D., and Beverley, P. C. L., 1983a, Production of human monoclonal antibody to X31 influenza virus nucleoprotein, J. Gen Virol. 64: 697–700.PubMedCrossRefGoogle Scholar
  6. Crawford, D. H., Barlow, M. J., Harrison, J. F., Winger, L., Huehns, E. R., 1983b, Production of human monoclonal antibody to rhesus D antigen, Lancet 1: 386–388.PubMedCrossRefGoogle Scholar
  7. Crawford, D. H., Huehns, E. R., and Epstein, M. A., 1983c, Therapeutic use of human monoclonal antibodies, Lancet 1: 1040.PubMedCrossRefGoogle Scholar
  8. Crawford, D. H., Barlow, M. J., Mulholland, N., McDougall, D. C. J., Zanders, E. D., Tippett, P., and Huehns, E. R., 1984, The production and characterisation of a human monoclonal antibody to the rhesus D antigen, Proc. Br. Blood Transfusion Soc. 1: 113–121.Google Scholar
  9. Doyle, A., Jones, T., Bidwell, J., and Bradley, B., In vitro production of human monoclonal antibody producing plasmacytoma, Hum. Immunol. In press.Google Scholar
  10. Epstein, M. A., 1978, Epstein–Barr virus—Discovery, properties and relationship to nasopharyngeal carcinoma, in: NasoPharyngeal Carcinoma; Aetiology and Control ( G. de-The, Y. Ho, and W. Davis, eds.), IARC, Lyon, pp. 333–345.Google Scholar
  11. Epstein, M. A., and Achong, B. G., 1979, The relationship of the virus to Burkitt’s lymphoma, in: The Epstein–Barr Virus ( M. A. Epstein and B. G. Achong, eds.), Springer, Berlin, pp. 321–337.CrossRefGoogle Scholar
  12. Fresen, U., and Zur Hausen, H., 1976, Establishment of EBNA-expressing cell lines by infection of Epstein–Barr virus (EBV)-genome-negative human lymphoma cells with different EBV strains, Int. J. Cancer 17: 161–166.PubMedCrossRefGoogle Scholar
  13. Gerber, P., 1972, Activation of Epstein–Barr virus by S-bromodeoxyuridine in virus-free human cells, Proc. Natl. Acad. Sci. USA 69: 83–85.PubMedCrossRefGoogle Scholar
  14. Gerber, P., Walsh, J. H., Rosenblum, E. N., and Purcell, R. H., 1969, Association of EB-virus infection with the post-perfusion syndrome, Lancet 1: 593–596.PubMedCrossRefGoogle Scholar
  15. Golden, H. D., Chang, R. S., Prescott, W., Simpson, E., and Cooper, T.Y., 1973, Leukocyte-transforming agent: Prolonged excretion by patients with mononucleosis and excretion by normal individuals, J. Infect. Dis. 127: 471–473.PubMedCrossRefGoogle Scholar
  16. Greaves, F. M., Brown, G., and Rickinson, A. B., 1975, Epstein–Barr virus binding sites on lymphocyte subpopulations and the origin of lymphoblasts in cultured lymphoid cell lines and in the blood of patients with infectious mononucleosis, Clin. Immunol. Immunopathol. 3: 514.PubMedCrossRefGoogle Scholar
  17. Henderson, E., Miller, G., Robinson, J., and Heston, L., 1977, Efficiency of transformation of lymphocytes by Epstein–Barr virus, Virology 76: 152–163.PubMedCrossRefGoogle Scholar
  18. Henle, G., Henle, W., and Diehl, V., 1968, Relation of Burkitt’s tumour-associated herpes-type virus to infectious mononucleosis, Proc. Natl. Acad. Sci. USA 59: 94–101.PubMedCrossRefGoogle Scholar
  19. Irie, R. F., Sze, L. L., and Saxton, R. E., 1982, Human antibody to OFA-1, a tumour antigen, produced in vitro by Epstein–Barr virus-transformed human B-lymphoid cell lines, Proc. Natl. Acad. Sci. USA 79: 5666–5670.PubMedCrossRefGoogle Scholar
  20. Kamo, I., Furukawa, S., Tada, A., Mano, Y., Iwasaki, Y., and Furuse, T., 1982, Monoclonal antobody to acetylcholine receptor: Cell line established from thymus of patient with myasthenia gravis, Science 215: 995–997.PubMedCrossRefGoogle Scholar
  21. Kaplan, M. E., and Clark, C., 1974, An improved rosetting assay for detection of human T lymphocytes, J. Immunol. Meth. 5: 131–135.CrossRefGoogle Scholar
  22. Katsuki, T., Hiruma, Y., Yamamoto, N., Abo, T., and Kumagai, K., 1977, Identification of the target cells in human B lymphocytes for transformation by Epstein–Barr virus, Virology 83: 287–294.PubMedCrossRefGoogle Scholar
  23. Kistler, P., and Nitschmann, H., 1962, Large scale production of human plasma fractions, Vox Sang. 7: 414–424.PubMedCrossRefGoogle Scholar
  24. Köhler, G., and Milstein, C., 1975, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature 256: 496.CrossRefGoogle Scholar
  25. Kozbor, D., and Roder, J. C., 1981, Requirements for the establishment of high-titred human monoclonal antibodies against tetanus toxoid using the Epstein–Barr virus technique, J. Immunol. 127: 1275–1280.PubMedGoogle Scholar
  26. Kozbor, D., Steinitz, M., Klein, G., Koskimies, S., and Makela, 0., 1979, Establishment of anti-TNP antibody producing human lymphoid lines by preselection for hapten binding followed by EBV transformation, Scand. J. Immunol. 10: 187–194.PubMedCrossRefGoogle Scholar
  27. Kozbor, D., Lagarde, A. E., and Roder, J. C., 1982, Human hybridomas constructed with antigenspecific Epstein–Barr virus-transformed cell lines, Proc. Natl. Acad. Sci. USA 79: 6651–6655.PubMedCrossRefGoogle Scholar
  28. Luka, J., Kallin, B., and Klein, G., 1979, Induction of the Epstein–Barr virus (EBV) cycle in latently infected cells by n-butyrate, Virology 94: 228–231.PubMedCrossRefGoogle Scholar
  29. Lundgren, K., Wahlgren, M., Troye-blomberg, M., Berzins, I. C., Perlmann, H., and Perlmann, P., 1983, Monoclonal anti-parasite and anti-RBC antibodies produced by stable EBV-transformed B cell lines from malaria patients, J. Immunol. 131: 2000–2003.PubMedGoogle Scholar
  30. Miller, G., 1975, Epstein—Barr herpes virus and infectious mononucleosis, Progr. Med. Virol. 20: 84–112.Google Scholar
  31. Miller, G., Shope, T., Lisco, H., Stitt, D., and Lipman, M., 1972, Epstein—Barr virus: Transformation cytopathic changes and viral antigens in squirrel monkey and marmoset leucocytes, Proc. Natl. Acad. Sci. USA 69: 383–387.PubMedCrossRefGoogle Scholar
  32. Miller, G., Niederman, J. C., and Andrews, L. L., 1973, Prolonged oropharyngeal excretion of Epstein—Barr virus after infectious mononucleosis, N. Eng. J. Med. 288: 229–232.CrossRefGoogle Scholar
  33. Moss, D. J., Rickinson, A. B., and Pope, J. H., 1978, Long-term T-cell-mediated immunity to Epstein—Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leucocytes, Int. J. Cancer 22: 662–668.PubMedCrossRefGoogle Scholar
  34. Muraguchi, A., Kishimoto, T., Miki, Y., Kuritoni, T., Kaieda, T., Yoskizaki, K., and Yamamura, Y., 1981, T Cell-replacing factor (TRF) induced IgG secretion in a human B blastoid cell line and demonstrations of acceptors for TRF, J. Immunol. 127: 412–416.PubMedGoogle Scholar
  35. Netzer, W., 1983, Monotech patents method for human—human hybridomas, Gene. Eng. News 1983 (January/February): 1.Google Scholar
  36. Nilsson, K., and Pontén, J., 1975, Classification and virological nature of established human haemopoetic cell lines, Int. J. Cancer 15: 321–341.PubMedCrossRefGoogle Scholar
  37. Nilsson, K., Klein, G., Henle, W., and Henle, G., 1971, The establishment of lymphoblastoid lines from adult and foetal human lymphoid cells and its dependence on EBV, Int. J. Cancer 8: 443–450.PubMedGoogle Scholar
  38. Palacios, R., Martinez-Maza, O., and Guy, K., 1983, Monoclonal antibodies against HLA DR antigens replace T helper cells in activation of B lymphocytes, Proc. Natl. Acad. Sci. USA 80: 3456–3460.PubMedCrossRefGoogle Scholar
  39. Pattengale, P. K., Smith, R. W., and Gerber, P., 1973, Selective transformation of B lymphocytes by EB virus, Lancet 2: 93–94.PubMedCrossRefGoogle Scholar
  40. Pope, J. H., Horne, M. K., and Scott, W., 1968, Transformation of foetal human leucocytes in vitro by filtrates of a human leukaemia cell line containing herpes-like virus, Int. J. Cancer 3: 857–866.PubMedCrossRefGoogle Scholar
  41. Pope, J. H., Scott, W., and Moss, D. J., 1974, Cell relationships in transformation of human leucocytes by Epstein—Barr virus, Int. J. Cancer 14: 122–129.PubMedCrossRefGoogle Scholar
  42. Reedman, B. M., and Klein, G., 1973, Cellular localisation of an Epstein—Barr virus (EBV)associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines, Int. J. Cancer 2: 499–520.CrossRefGoogle Scholar
  43. Rickinson, A. B., Moss, D. J., and Pope, J. H., 1979, Long-term T-cell mediated immunity to Epstein—Barr virus in man. II Components necessary for regression in virus infected leucocyte culture, Int. J. Cancer 23: 610–617.PubMedCrossRefGoogle Scholar
  44. Rosen, A., Gergely, P., Jondal, M., Klein, G., and Britton, S., 1977, Polyclonal Ig production after Epstein—Barr virus infection of human lymphocytes in vitro, Nature 267: 52–54.PubMedCrossRefGoogle Scholar
  45. Rosen, A., Persson, K., and Klein, G., 1983, Human monoclonal antibodies to a genus-specific chlamydial antigen, produced by EBV-transformed B cells, J. Immunol. 130: 2899–2902.PubMedGoogle Scholar
  46. Seigneurin, J. M., Desgranges, C., Seigneurin, D., Paine, J., Renversez, J. C., Jacquemond, B., and Micouin, C., 1983, Herpes simplex virus glycoprotein D: Human monoclonal antibody produced by bone marrow cell line, Science 221: 173–175.PubMedCrossRefGoogle Scholar
  47. Souhami, R. L., Babbage, J., and Callard, R. E., 1981, Specific in vitro antibody response to varicella zoster, Clin. Exp. Immunol. 46: 98–105.PubMedGoogle Scholar
  48. Stein, L. D., and Sigal, N. H., 1983, Limiting dilution analysis of Epstein—Barr virus-induced immunoglobulin production, Cell. Immunol. 79: 309–319.PubMedCrossRefGoogle Scholar
  49. Steinitz, M., Klein, G., Koskimies, S., and Makela, O., 1977, EB virus induced B lymphocyte cell lines producing specific antibody, Nature 269: 420–422.PubMedCrossRefGoogle Scholar
  50. Steinitz, M., Koskimies, S., Klein, G., and Makela, O., 1979, Establishment of specific antibody producing human lines by antigen preselection and Epstein—Barr (EBV) transformation, Clin. Lab. Immunol. 2: 1–7.Google Scholar
  51. Steinitz, M., Izak, G., Cohen, S., Ehrenfeld, M., and Flechner, I., 1980, Continuous production of monoclonal rheumatoid factor by EBV-transformed lymphocytes, Nature 287: 443–445.PubMedCrossRefGoogle Scholar
  52. Steinitz, M., Tauier, S., and Goldfarb, A., 1984, Human anti-pneumococci antibody produced by an Epstein—Barr virus (EBV)-immortalised cell lines, J. Immunol. 132: 877–882.PubMedGoogle Scholar
  53. Winger, L., Winger, C., Shastry, P., Russell, A., and Longenecker, M., 1983, Efficient generation in vitro of monoclonal Epstein—Barr virus-transformants producing specific antibody to a variety of antigens, without prior deliberate immunisation, Proc. Natl. Acad. Sci. USA 80: 4484–4488.PubMedCrossRefGoogle Scholar
  54. Yarchoau, R., Tosato, G., Blaese, R. A., Simon, R. M., and Nelson, D. L., 1983, Limiting dilution analysis of Epstein—Barr virus-induced immunoglobulin production by human B cells, J. Exp. Med. 157: 1–14.CrossRefGoogle Scholar
  55. Zerbini, M., and Emberg, I., 1983, Can Epstein—Barr virus infect and transform all the B-lymphocytes of human cord blood?, J. Gen. Viral. 64: 539–547.CrossRefGoogle Scholar
  56. Zurawski, V. R., Spedden, S. E., Black, P. H., and Haber, E., 1978, Clones of human lymphoblastoid cell lines producing antibody to tenanus toxoid, in: Lymphocyte Hybridomas,Volume 81 ( F. Melchers, M. Potter, N. Warner, eds.), Springer, Berlin, pp. 152–155.Google Scholar
  57. Zur Hausen, H., O’Neill, F. J., Freese, U. K., and Hecker, E., 1978, Persisting oncogenic herpes virus induced by the tumor promoter TPA, Nature 272: 373–375.PubMedCrossRefGoogle Scholar
  58. Franklin, R.M., 1982, Microcomputer inventory systems for stored cell lines. J. Immunol. Meth. 54:141–157.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • Dorothy H. Crawford
    • 1
  1. 1.Department of Haematology, Faculty of Clinical SciencesUniversity College LondonLondonEngland

Personalised recommendations